As the readouts from three late-stage Alzheimer’s disease drug candidates draw nearer, hopes are again rising that a breakthrough may finally be possible – but given the string of failures over the last 20 years, many are skeptical about the chances of success for the beta-amyloid targeting antibody therapies.
Eli Lilly believes its patient-stratification approach could give it the edge, but its readout looks set to be the last of the trio; Biogen and Eisai’s lecanemab...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?